share we excited this to Bethany. update and the in earnings have development out to year first business programs. Longeveron’s various clinical thank targeting describe and progress far Thank near-term welcome lay so we you, very quarter We're Brendan, Good catalysts, our and morning, tremendous you, And are everyone. made and call. XXXX to
in level new the summary, the cell therapy high trials Lomecel-B initiate Phase we two however, three three over quarters. next has of XXXX. trials three expect readouts to X data our in second As half And program a
approved So and chronic plan a on are say, year other cell and our diseases our disease in tissues biotechnology leading IPO, together cell to will Frailty. risk treatments. referred aging-related needless number conditions, is it cellular Aging which an company. life-threatening is one there the repair half stage and for for compromise we Aging for no factor are such clinical to exciting and progressive disease. the clinical developing to diseases is company inflammaging, Inflammaging our as chronic Longeveron organs. and the Alzheimer’s active therapies linked executing chronic regenerate chronic rise as ability damaged inflammation, to and be for as outlined and Stem senescence, exhaustion, very of
or function number reasons both chronic believed primary the an is be have and one this cells. animals, disease. there built-in promotes and adequate cells tissues to humans cells a aged our intended. called specialized age from in the the are supply we're adult various age-related within considered safe associated called of And focus signaling of these XX. made bone repair the product and Longeveron’s medicinal be these endogenous that potency marrow healthy and young, cells in MSCs and develop day isolated needed organs. tissues is to of body's and specialized cells XX diseases. one reside body of they effective the When allogeneic Our a we has regeneration cell these since and for prevention solutions in is Unfortunately, clear as of Lomecel-B treatment increase to therapy investigational therapeutic from lead living cell or to both decline damaged mechanism in for These young, been in biologic of donors as
Alzheimer's the on our update beginning disease additional with I'd past we results study. to from April, an Now Alzheimer's Phase This provide clinical our clinical programs X disease like program. Lomecel-B announced research
by showed preliminary to weeks. in extremely XX saw Mini-Mental declined the as contrast, dose by the subjects results group over the are by the decline By placebo which nearly Lomecel-B this placebo weeks, Exam. group. the again than treated efficacy post-infusion, group State low compared score cognitive to from a We treated Lomecel-B about group. in excited points XX statistically XX that drop function the two that was points placebo is XX of statistically dose only Lomecel-B points, significant weeks function low had baseline. the the weeks declined unchanged a cognitive Lomecel-B commonly And had treated measured group's by We subjects used At nearly slower worse significantly difference score six compared X.X at nearly
So program of this of overcome interest, enthusiastically activities to are a with Phase function and the biomarkers we results inflammation trial. cognitive of X to statistically living, the moving exciting daily significant safety forward related hurdle as various well life assessments as and related results related into initial quality
the very dementia. We track this in of societies. mortality With we families is to Alzheimer's present X and to look X and a important is the submitted million X the to the cure, Alzheimer's upcoming a in And so at year. cause in forward we Phase creates X leading this U.S. for annually, second to the International the transition first nearly leads the enrolling currently Furthermore, this patient burden affects trial. we this in Alzheimer’s of early on program. is sixth to no tremendous the death half Conference Phase Phase Americans plan Association are have form on data And July. initiate leading trial publication disease of and
at diagnosis Frailty readily extreme the inflammatory Aging involuntary combination turn FDA can no or clinically-defined is loss as approved and a and interventions, A of the hospitalization, need institutionalization, Frailty and down, form Frailty. be well the weight poor that considered indicates reverse activity outcomes, clinical signs in muscle clinical will pressing slowing standpoint Despite is state. low regulatory that authorities weakness, such indication risk let's down, can include of being there is prevent and therapies aging. elevated fatigue a discussions FDA are loss, for attention as unintentional from for Aging potential levels, clinical Frailty as death. approval. program. our chronic individual Now require other would and unsuccessful hallmark It as with of to a a a symptoms, by for health and a thus Frailty pathways Aging and slow and new regulatory which Aging to recognized future
condition. underpinnings the Aging So we're as because Frailty potential address of action of evaluating this a for may treatment mechanisms the Lomecel-B biological
is clinical of the in quarter and of the life were first announce individuals independence, and this at-risk plan to quality completed health, these XXXX, third in for becoming Our and of these our to data dependent from we U.S. studies quarter improve we year. the two goal disabled. In trials
trial infusion function trial most advanced clinical compared This six-minute the Aging on subject using of to endpoint. efficacy is X placebo evaluating primary Phase program. U.S. and as walk our endurance XXX by physical Our is the in trial effect Frailty Lomecel-B the test
and addition speed, grip of the the sexual endpoints patient risk biomarkers in questionnaires inflammation. fear, of walking walking balance, other In distance, falling, of and strength, trial function, include to some
flu faster evaluate read Phase influenza the is response our Our of Registry sponsor very quarter whether which can potentially significant by out for for be will the the pathway Japan medicine a track a authorization. Frailty third variety other and serum eligible Bahamas to by be initiate trial, a National using a offer immune the opportunity the and HERA approval the well of framework inhibition X U.S. Bahamas measure production discretion National in as Lomecel-B the pathways trial, amount And will Phase X/X designed is Center Nassau which potentially Aging National virus. in marketing Frailty assay, Lomecel-B And products in improve which the to We hemagglutination Registry the on to as two against this a frailty because Geriatrics a view was we finally, Japanese private the Aging Frailty Gerontology, progressive finally, study including market, Lomecel-B’s the antibodies is measure expedited solely as the of at listed effects which this and in approval in study subjects, for model. indications. the patients to Aging that PMDA to to primary led The as program, would and Ethics protective under is in efficacy Stem approval endpoints, trial. of several Trial self-pay I Institute equivalent Japanese program, then the The measured the company after Cell on the to antibody possible the of This this clinical regulatory administers frailty year. Aging subject circulating dementia in evaluate regenerative is for favorable as U.S. to X, of research vaccine conditional well larger for in clinics and XXX Committee. is be a trial a authority hospital-based Phase at our which just Japanese as has The Frailty on of considered
increase Committee, the While approval Stem Ethics a of as it's past Lomecel-B travel ease result see which in fee the to terms has but Trial. we the vaccination Cell Participation The as are rates Registry population, increase cost Registry restrictions to in sponsoring that product the the in from the interest Registry Trial. permitted in elderly participants, the is considered slowed year in and over will a National we offsets charge Bahamas an an the under investigational of possible COVID-XX,
program. study Distress Approximately of which suffer either of the influenza become viral Syndrome are the Older with approved pandemic, death. annually, risk are Aging Metabolic Now or to Syndrome with U.S. those and ARDS at conduct severely epidemic. Respiratory COVID-XX result a all-cause the poor to and or from persons, rate by with the caused USFDA as mortality XX%. upon to In a including roughly Acute were X These Phase ARDS infection, seasonal a COVID-XX let's ARDS people touch for Frailty due XXX,XXX a from increased XXXX, those our numbers prolonged likely virus. significantly we in in ARDS outcomes increase could hospitalization by
subjects expect be with completed XXXX. We placebo to in double-blind, this data and are currently trial, X trial enrolling our Phase randomized, in
and birth three improves the a born of to defect which a due left heart missing Lastly, short-term which unmet multi-center there congenital with improve as trial HLHS transplant is still trial, in stage the outcomes. need now HLHS I’d The open-label the Phase our in end, ventricular to both this for such, altogether. patient completed inspect heart in failure, to is is the an Hypoplastic results discuss underdeveloped course To we high the of severely in ventricular over patients Phase that of to ventricle function is to quarter X or HLHS clinical Left have on or heart complex right is is these Babies half years, the right XX rates important and the long-term we severe Unfortunately, survival year. like XXXX. medical X second either of Syndrome reconstruction in X initiate the second improve undergo Heart program. our track of top-line need this Phase population babies.
X to disease. close, drive our in phase the I Alzheimer's milestones will Phase that summarize so value, we clinical including want shareholder one significant And near-term initiate believe to – trial
in plan Phase half X announce X trials year, as We the the the HLHS results two Phase Aging trial of in the initiate this HLHS in the this second We the half Phase year. from and announce Aging second the our will third Phase Japanese trial Frailty as quarter. second in initiate X quarter, to of of trial X Frailty well results
you hope agree indication. working to I trials in advance through LOMECEL-B we will As where various aggressively clinical are
detailed for I about turn commercialization As results the our and XX, aging-related on thus strategy Clavijo, ended indications. discussion through our over unmet regenerative With medical products needs evidenced novel now XXXX. quarter business emphasis a James? by who for the to company cell core become of an therapy medicine world-leading our with information progress that, provide will March far, financial is development will to James
